BACKGROUND: Secondary analyses of clinical trial data suggest that, compared with other agents, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with lower risk of incident atrial fibrillation (AF) in patients with heart failure, but data from the hypertension trials have been inconsistent. Information is scant about the association of beta-blocker use with AF risk in hypertensive patients without heart failure. METHODS: We conducted a population-based case-control study to determine whether antihypertensive treatment with ACE inhibitors/ARBs or beta-blockers, compared with diuretics, was associated with the risk of incident AF in a community practice setting. All patients (810 AF cases, 1,512 control subjects) were members of Group Health (GH), an integrated health-care delivery system, were pharmacologically treated for hypertension, and did not have heart failure. Medical records were reviewed to confirm the diagnosis of incident AF and to collect information on medical conditions and health behaviors. Information on antihypertensive medications was obtained from a pharmacy database. RESULTS: Single-drug users of an ACE inhibitor/ARB had a lower risk of incident AF compared with single-drug users of a diuretic (adjusted odds ratio 0.63, 95% confidence interval 0.44-0.91). Single-drug use of beta-blockers was not significantly associated with lower AF risk (odds ratio 1.05, 95% confidence interval 0.73-1.52), and also none of the most commonly used two-drug regimens was significantly associated with AF risk, in comparison with single-drug use of diuretic. CONCLUSIONS: In a general hypertensive population without heart failure, single-drug use of ACE inhibitors/ARBs was associated with lower AF risk.
BACKGROUND: Secondary analyses of clinical trial data suggest that, compared with other agents, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with lower risk of incident atrial fibrillation (AF) in patients with heart failure, but data from the hypertension trials have been inconsistent. Information is scant about the association of beta-blocker use with AF risk in hypertensivepatients without heart failure. METHODS: We conducted a population-based case-control study to determine whether antihypertensive treatment with ACE inhibitors/ARBs or beta-blockers, compared with diuretics, was associated with the risk of incident AF in a community practice setting. All patients (810 AF cases, 1,512 control subjects) were members of Group Health (GH), an integrated health-care delivery system, were pharmacologically treated for hypertension, and did not have heart failure. Medical records were reviewed to confirm the diagnosis of incident AF and to collect information on medical conditions and health behaviors. Information on antihypertensive medications was obtained from a pharmacy database. RESULTS: Single-drug users of an ACE inhibitor/ARB had a lower risk of incident AF compared with single-drug users of a diuretic (adjusted odds ratio 0.63, 95% confidence interval 0.44-0.91). Single-drug use of beta-blockers was not significantly associated with lower AF risk (odds ratio 1.05, 95% confidence interval 0.73-1.52), and also none of the most commonly used two-drug regimens was significantly associated with AF risk, in comparison with single-drug use of diuretic. CONCLUSIONS: In a general hypertensive population without heart failure, single-drug use of ACE inhibitors/ARBs was associated with lower AF risk.
Authors: Rozenn N Lemaitre; Bruce M Psaty; Susan R Heckbert; Nicholas L Smith; W T Longstreth; Frits R Rosendaal Journal: Arterioscler Thromb Vasc Biol Date: 2002-06-01 Impact factor: 8.311
Authors: Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano Journal: Circulation Date: 2006-08-15 Impact factor: 29.690
Authors: L Hansson; L H Lindholm; T Ekbom; B Dahlöf; J Lanke; B Scherstén; P O Wester; T Hedner; U de Faire Journal: Lancet Date: 1999-11-20 Impact factor: 79.321
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Roland E Schmieder; Sverre E Kjeldsen; Stevo Julius; Gordon T McInnes; Alberto Zanchetti; Tsushung A Hua Journal: J Hypertens Date: 2008-03 Impact factor: 4.844
Authors: Nicholas L Smith; Kenneth M Rice; Edwin G Bovill; Mary Cushman; Joshua C Bis; Barbara McKnight; Thomas Lumley; Nicole L Glazer; Astrid van Hylckama Vlieg; Weihong Tang; Abbas Dehghan; David P Strachan; Christopher J O'Donnell; Jerome I Rotter; Susan R Heckbert; Bruce M Psaty; Frits R Rosendaal Journal: Blood Date: 2010-12-16 Impact factor: 22.113
Authors: Laura B Harrington; Noel S Weiss; Kerri L Wiggins; Susan R Heckbert; Barbara McKnight; Marc Blondon; Nancy F Woods; Andrea Z LaCroix; Bruce M Psaty; Nicholas L Smith Journal: Menopause Date: 2016-02 Impact factor: 2.953
Authors: Evan L Thacker; Paul N Jensen; Bruce M Psaty; Barbara McKnight; W T Longstreth; Sascha Dublin; Katherine M Newton; Nicholas L Smith; David S Siscovick; Susan R Heckbert Journal: Ann Pharmacother Date: 2015-01-27 Impact factor: 3.154
Authors: Evan L Thacker; Barbara McKnight; Bruce M Psaty; W T Longstreth; Sascha Dublin; Paul N Jensen; Katherine M Newton; Nicholas L Smith; David S Siscovick; Susan R Heckbert Journal: J Gen Intern Med Date: 2012-09-13 Impact factor: 5.128
Authors: Renu K Garg; Nicole L Glazer; Kerri L Wiggins; Katherine M Newton; Evan L Thacker; Nicholas L Smith; David S Siscovick; Bruce M Psaty; Susan R Heckbert Journal: Pharmacoepidemiol Drug Saf Date: 2010-12-23 Impact factor: 2.890
Authors: Steven A Lubitz; Kathryn L Lunetta; Honghuang Lin; Dan E Arking; Stella Trompet; Guo Li; Bouwe P Krijthe; Daniel I Chasman; John Barnard; Marcus E Kleber; Marcus Dörr; Kouichi Ozaki; Albert V Smith; Martina Müller-Nurasyid; Stefan Walter; Joanne M Murabito; Moritz F Sinner; Vilmundur Gudnason; Stephan B Felix; Winfried März; Mina Chung; Christine M Albert; Bruno H Stricker; Toshihiro Tanaka; Susan R Heckbert; J Wouter Jukema; Alvaro Alonso; Emelia J Benjamin; Patrick T Ellinor; Sunil K Agarwal; Joshua C Bis; Jennifer A Brody; Lin Y Chen; Brendan M Everett; Ian Ford; Oscar H Franco; Tamara B Harris; Albert Hofman; Stefan Kääb; Saagar Mahida; Sekar Kathiresan; Michiaki Kubo; Lenore J Launer; Peter W MacFarlane; Jared W Magnani; Barbara McKnight; David D McManus; Annette Peters; Bruce M Psaty; Lynda M Rose; Jerome I Rotter; Guenther Silbernagel; Jonathan D Smith; Nona Sotoodehnia; David J Stott; Kent D Taylor; Andreas Tomaschitz; Tatsuhiko Tsunoda; Andre G Uitterlinden; David R Van Wagoner; Uwe Völker; Henry Völzke Journal: J Am Coll Cardiol Date: 2014-01-30 Impact factor: 24.094
Authors: T Horio; M Akiyama; Y Iwashima; F Yoshihara; S Nakamura; T Tokudome; M Okutsu; H Tanaka; I Komatsubara; N Okimoto; S Kamakura; Y Kawano Journal: J Hum Hypertens Date: 2016-12-29 Impact factor: 3.012
Authors: Gerald S Bloomfield; Tecla M Temu; Constantine O Akwanalo; Peng-Sheng Chen; Wilfred Emonyi; Susan R Heckbert; Myra M Koech; Imran Manji; Changyu Shen; Matteo Vatta; Eric J Velazquez; Jennifer Wessel; Sylvester Kimaiyo; Thomas S Inui Journal: Am Heart J Date: 2015-06-14 Impact factor: 4.749